Company research
Adicet Bio, Inc.
CIK 1720580Updated Nov 6, 2026
SecurityACET · NASDAQ · equity
Name history
resTORbio, Inc. · through Aug 21, 2020
ACET price & chart
Loading TradingView…
NASDAQ:ACET on TradingView ↗About the company
Adicet Bio, Inc. is a clinical-stage biotechnology company discovering and developing a broad pipeline of allogeneic gamma delta T cell therapies, engineered with chimeric antigen receptors (CARs), alongside differentiated in vivo CAR-T therapies with the potential to redefine treatment across autoimmune diseases, hematologic malignancies and solid tumors. For more information, please visit our website at https://www.adicetbio.com.
In the news
No coverage from other publishers is available.
Seeking Alpha
Adicet Bio, Inc. (ACET) Discusses Positive Prula-cel Data and Plans for Pivotal Study in Lupus Nephritis - Slideshow ↗
Adicet Bio, Inc. (ACET) Discusses Positive Prula-cel Data and Plans for Pivotal Study in Lupus Nephritis Transcript ↗
SEC disclosures
Adicet Bio, Inc. files 8-K: Material Event ↗
Recent filings
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
SCHEDULE 13G/A - filed by FRANKLIN TEMPLETON INC regarding Adicet Bio, Inc.
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 140,479,000Source | 245,962,000Source | 148,166,000Source | 162,972,000Source | 268,842,000Source | 169,382,000Source | 191,271,000Source | 293,095,000Source | 192,355,000Source | 220,219,000Source | 207,295,000Source | 330,690,000Source |
| Property, Plant and Equipment, NetUSD | 17,994,000Source | 24,088,000Source | 14,028,000Source | 19,549,000Source | 24,041,000Source | 15,183,000Source | 21,108,000Source | 25,407,000Source | 16,532,000Source | 22,524,000Source | 26,777,000Source | 28,710,000Source |
| GoodwillUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 19,462,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 29,099,000Source | 105,482,000Source | 33,131,000Source | 34,720,000Source | 224,069,000Source | 36,245,000Source | 28,133,000Source | 159,711,000Source | 38,918,000Source | 56,495,000Source | 159,711,000Source | 257,656,000Source |
| Assets, CurrentUSD | 106,494,000Source | 206,316,000Source | 120,763,000Source | 127,740,000Source | 228,353,000Source | 140,071,000Source | 153,563,000Source | 250,350,000Source | 160,926,000Source | 180,136,000Source | 162,272,000Source | 261,038,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 3,396,000Source | 4,251,000Source | 2,573,000Source | 2,777,000Source | 4,284,000Source | 2,479,000Source | 3,124,000Source | 2,761,000Source | 2,396,000Source | 3,833,000Source | 2,561,000Source | 3,382,000Source |
| Operating Lease, Right-of-Use AssetUSD | 11,901,000Source | 15,050,000Source | 9,538,000Source | 12,555,000Source | 15,855,000Source | 10,239,000Source | 13,383,000Source | 16,647,000Source | 10,927,000Source | 14,228,000Source | 17,424,000Source | 20,269,000Source |
| Other Assets, NoncurrentUSD | 110,000Source | 508,000Source | 80,000Source | 225,000Source | 593,000Source | 78,000Source | 314,000Source | 691,000Source | 76,000Source | 428,000Source | 822,000Source | 1,211,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 31,337,000Source | 34,431,000Source | 28,028,000Source | 29,600,000Source | 33,731,000Source | 29,317,000Source | 29,825,000Source | 34,291,000Source | 33,145,000Source | 33,610,000Source | 37,120,000Source | 38,352,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | — |
| Common Stock, Value, IssuedUSD | 8,000Source | 8,000Source | 1,000Source | 8,000Source | 8,000Source | 1,000Source | 8,000Source | 8,000Source | 10,000Source | 8,000Source | 4,000Source | 4,000Source |
| Retained Earnings (Accumulated Deficit)USD | -584,181,000Source | -469,167,000Source | -656,299,000Source | -557,325,000Source | -438,689,000Source | -634,941,000Source | -526,108,000Source | -408,788,000Source | -614,697,000Source | -497,894,000Source | -380,772,000Source | -238,114,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 56,000Source | 121,000Source | -105,000Source | -41,000Source | — | -37,000Source | -9,000Source | — | 102,000Source | 16,000Source | — | 0Source |
| Stockholders' Equity Attributable to ParentUSD | 109,142,000Source | 211,531,000Source | 120,138,000Source | 133,372,000Source | 235,111,000Source | 140,065,000Source | 161,446,000Source | 258,804,000Source | 159,210,000Source | 186,609,000Source | 170,175,000Source | 292,338,000Source |
| Additional Paid in Capital, Common StockUSD | 693,259,000Source | 680,569,000Source | 776,541,000Source | 690,730,000Source | 673,792,000Source | 775,042,000Source | 687,555,000Source | 667,584,000Source | 773,795,000Source | 684,479,000Source | 550,943,000Source | 530,448,000Source |
| Liabilities and EquityUSD | 140,479,000Source | 245,962,000Source | 148,166,000Source | 162,972,000Source | 268,842,000Source | 169,382,000Source | 191,271,000Source | 293,095,000Source | 192,355,000Source | 220,219,000Source | 207,295,000Source | 330,690,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 18,941,000Source | 19,394,000Source | 18,001,000Source | 17,079,000Source | 17,904,000Source | 18,298,000Source | 16,447,000Source | 17,461,000Source | 21,531,000Source | 19,392,000Source | 19,287,000Source | 19,707,000Source |
| Operating Lease, Liability, CurrentUSD | 2,925,000Source | 3,278,000Source | 2,655,000Source | 2,953,000Source | 3,421,000Source | 2,748,000Source | 2,983,000Source | 3,322,000Source | 2,837,000Source | 3,132,000Source | 3,221,000Source | 2,492,000Source |
| Accounts Payable, CurrentUSD | 4,287,000Source | 2,500,000Source | 3,592,000Source | 3,292,000Source | 1,899,000Source | 2,929,000Source | 4,403,000Source | 2,542,000Source | 4,739,000Source | 4,830,000Source | 2,625,000Source | 4,404,000Source |
| Operating Lease, Liability, NoncurrentUSD | 11,645,000Source | 14,921,000Source | 9,401,000Source | 12,405,000Source | 15,711,000Source | 10,161,000Source | 13,262,000Source | 16,714,000Source | 10,910,000Source | 14,102,000Source | 17,703,000Source | 18,531,000Source |
| Other Liabilities, NoncurrentUSD | 125,000Source | 116,000Source | 0Source | 116,000Source | 116,000Source | 0Source | 116,000Source | 116,000Source | 62,000Source | 116,000Source | 130,000Source | 114,000Source |
| Additional Financial Items | ||||||||||||
| Dividends PayableUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Short-term Investments | — | —Source | — | — | — | — | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -20,244,000Source | -28,214,000Source | -116,803,000Source | -117,122,000Source | -142,658,000Source | -69,790,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation and amortization | — | — | —Source | —Source | —Source | — | —Source | —Source | —Source | —Source | —Source | —Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | 2,500,000Source | 6,800,000Source | 1,400,000Source | 2,900,000Source | 1,303,000Source | 3,180,000Source | 14,267,000Source | 22,233,000Source | 20,259,000Source | 17,126,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -1,800,000Source | 629,000Source | 1,029,000Source | 1,106,000Source | -1,683,000Source | 1,710,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -21,490,000Source | -25,397,000Source | -95,246,000Source | -92,378,000Source | -93,717,000Source | -44,765,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 18,879,000Source | -2,861,000Source | 2,393,000Source | -119,242,000Source | -4,464,000Source | -16,782,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 37,000Source | 1,492,000Source | 1,738,000Source | 1,118,000Source | 4,464,000Source | 16,782,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | 3,000Source | — | 65,000Source | 104,000Source | 104,000Source | 141,000Source | 150,000Source | 3,234,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -65,000Source | -104,000Source | 75,245,000Source | 111,307,000Source | 236,000Source | 41,509,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -2,676,000Source | -28,362,000Source | -17,608,000Source | -100,313,000Source | -97,945,000Source | -20,038,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 32,002,000Source | 105,482,000Source | 36,000,000Source | 37,623,000Source | 39,114,000Source | 31,036,000Source | 41,790,000Source | 59,398,000Source | 159,711,000Source | 257,656,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 2,529,000Source | 6,777,000Source | 1,441,000Source | 2,908,000Source | 1,303,000Source | 3,180,000Source | 14,267,000Source | 22,233,000Source | 20,259,000Source | 17,126,000Source |
| DepreciationUSD | — | — | 1,573,000Source | 1,593,000Source | 1,199,000Source | 1,655,000Source | 1,342,000Source | 1,680,000Source | 6,381,000Source | 6,468,000Source | — | — |
| Dividends PayableUSD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Gain (Loss) on Disposition of AssetsUSD | — | — | — | — | — | — | — | — | -103,000Source | — | 4,000Source | -55,000Source |
| Gain (Loss) on Disposition of Intangible AssetsUSD | — | — | — | — | — | — | — | — | — | — | — | 200,000Source |
| Gain (Loss) on Disposition of Assets for Financial Service OperationsUSD | — | — | — | — | — | — | — | — | — | — | — | 100,000Source |
| General and Administrative ExpenseUSD | — | — | 5,099,000Source | 6,900,000Source | 3,851,000Source | 3,968,000Source | 4,083,000Source | 7,071,000Source | 22,987,000Source | 28,292,000Source | 26,533,000Source | 26,295,000Source |
| GoodwillUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 19,462,000Source |
| Goodwill, Impairment LossUSD | — | — | — | 0Source | — | — | — | — | — | 0Source | 19,462,000Source | 0Source |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 143,000Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -26,856,000Source | -30,478,000Source | -21,358,000Source | -31,217,000Source | -20,244,000Source | -28,214,000Source | -116,803,000Source | -117,122,000Source | -142,658,000Source | -69,790,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -26,856,000Source | -30,478,000Source | -21,358,000Source | -31,217,000Source | -20,244,000Source | -28,214,000Source | -116,803,000Source | -117,122,000Source | -142,658,000Source | -69,790,000Source |
| Operating ExpensesUSD | — | — | 27,952,000Source | 33,153,000Source | 22,301,000Source | 32,392,000Source | 21,570,000Source | 29,885,000Source | 122,114,000Source | 127,615,000Source | 152,038,000Source | 97,541,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -64,000Source | -54,000Source | -60,000Source | -223,000Source | 7,000Source | -12,000Source | -430,000Source | -217,000Source | -573,000Source | -919,000Source |
| Other Operating Income (Expense), NetUSD | — | — | 76,000Source | 55,000Source | 82,000Source | 223,000Source | 16,000Source | 12,000Source | 466,000Source | 221,000Source | — | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | 0Source | 0Source | 19,266,000Source | 0Source | 0Source |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | 0Source | 1,000Source | 195,000Source | 4,000Source | 1,315,000Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -27,952,000Source | -33,153,000Source | -22,301,000Source | -32,392,000Source | -21,570,000Source | -29,885,000Source | -122,114,000Source | -127,615,000Source | -152,038,000Source | -72,551,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -64,000Source | -54,000Source | -60,000Source | -223,000Source | 7,000Source | -12,000Source | -430,000Source | -217,000Source | -573,000Source | -919,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -26,856,000Source | -30,478,000Source | -21,215,000Source | -31,217,000Source | -20,244,000Source | -28,214,000Source | -116,803,000Source | -117,122,000Source | -142,658,000Source | -69,790,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 143,000Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -26,856,000Source | -30,478,000Source | -21,358,000Source | -31,217,000Source | -20,244,000Source | -28,214,000Source | -116,803,000Source | -117,122,000Source | -142,658,000Source | -69,790,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.29Source | -0.34Source | -1.99Source | -5.48Source | -1.88Source | -4.96Source | -16.95Source | -1.33Source | -3.31Source | -1.7Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.29Source | -0.34Source | -1.99Source | -5.48Source | -1.88Source | -4.96Source | -16.95Source | -1.33Source | -3.31Source | -1.7Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 91,086,464Source | 90,846,293Source | 10,745,553Source | 5,692,816Source | 10,744,621Source | 5,691,965Source | 6,891,336Source | 87,866,435Source | 43,042,405Source | 41,080,286Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 91,086,464Source | 90,846,293Source | 10,745,553Source | 5,692,816Source | 10,744,621Source | 5,691,965Source | 6,891,336Source | 87,866,435Source | 43,042,405Source | 41,080,286Source |
| Additional Financial Items | ||||||||||||
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | 1,600,000Source | 1,600,000Source | 1,200,000Source | — | 1,342,000Source | 1,680,000Source | 6,381,000Source | 6,468,000Source | 6,098,000Source | 2,575,000Source |
| General and Administrative ExpenseUSD | — | — | 5,099,000Source | 6,900,000Source | 3,851,000Source | 3,968,000Source | 4,083,000Source | 7,071,000Source | 22,987,000Source | 28,292,000Source | 26,533,000Source | 26,295,000Source |
| Goodwill, Impairment LossUSD | — | — | — | 0Source | — | — | — | — | — | 0Source | 19,462,000Source | 0Source |
| Interest and Other IncomeUSD | — | — | 1,172,000Source | 2,730,000Source | 1,168,000Source | 1,398,000Source | 1,342,000Source | 1,683,000Source | 5,777,000Source | 10,714,000Source | 9,978,000Source | 3,760,000Source |
| Interest ExpenseUSD | — | — | 12,000Source | 1,000Source | 22,000Source | 0Source | 23,000Source | 0Source | 36,000Source | 4,000Source | 25,000Source | 80,000Source |
| Interest Income, OperatingUSD | — | — | 1,172,000Source | 2,730,000Source | 1,168,000Source | 1,398,000Source | 1,342,000Source | 1,683,000Source | 5,777,000Source | 10,714,000Source | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -26,856,000Source | -30,478,000Source | -21,358,000Source | -31,217,000Source | -20,244,000Source | -28,214,000Source | -116,803,000Source | -117,122,000Source | -142,658,000Source | -69,790,000Source |
| Operating ExpensesUSD | — | — | 27,952,000Source | 33,153,000Source | 22,301,000Source | 32,392,000Source | 21,570,000Source | 29,885,000Source | 122,114,000Source | 127,615,000Source | 152,038,000Source | 97,541,000Source |
| Other Operating Income (Expense), NetUSD | — | — | 76,000Source | 55,000Source | 82,000Source | 223,000Source | 16,000Source | 12,000Source | 466,000Source | 221,000Source | — | — |
| Research and Development ExpenseUSD | — | — | 22,853,000Source | 26,253,000Source | 18,450,000Source | 28,424,000Source | 17,487,000Source | 22,814,000Source | 99,127,000Source | 99,323,000Source | 106,043,000Source | 71,246,000Source |
Offerings
Registration 333-294265
Filing attachments
acet-ex99_1.htm · 8-K · 2026-11-05
Adicet Bio Reports Third Quarter 2026 Financial Results and Provides Business Updates Phase 1 data for prulacabtagene leucel (prula-cel, formerly ADI-001) demonstrated durable responses and a favorable safety profile in patients with systemic lupus erythematosus (SLE) with or without lupus nephritis (LN) Pivotal LN study startup activities underway; FDA engagement planned in 4Q/2026 to discuss pivotal expansion into lupus patients without nephritis Regulatory update and 12-month follow-up dat…
Read attachment ↗acet-ex99_1.htm · 8-K · 2026-09-28
Adicet Bio Announces Positive Safety and Efficacy Data from Prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis - Prula-cel shown to be generally well tolerated with no CRS greater than Grade 2 and no IEC-HS or ICANS - -At 12-months, 54% of evaluable patients achieved DORIS remission and 50% of patients achieved CRR- -All patients discontinued immunosuppressants - - All but one patient tapered background steroids to ≤5 mg prednison…
Read attachment ↗acet-ex99_2.htm · 8-K · 2026-09-28
September 28, 2026 Prula-cel Clinical Data Update Forward-Looking Statements This presentation contains “forward-looking statements” of Adicet within the meaning of the Private Securities Litigation Reform Act of 1995 relating to the business and operations of Adicet. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would” and similar expressions are intended to identify forward-looking…
Read attachment ↗acet-ex99_1.htm · 8-K · 2026-09-08
EX-99.1 2 acet-ex99_1.htm EX-99.1 September 2026 Investor Overview Forward-Looking Statements This presentation contains “forward-looking statements” of Adicet within the meaning of the Private Securities Litigation Reform Act of 1995 relating to the business and operations of Adicet. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would” and similar expressions are intended to ide…
Read attachment ↗acet-ex99_1.htm · 8-K · 2026-09-01
EX-99.1 2 acet-ex99_1.htm EX-99.1 EX-99.1 Adicet Bio Announces Completion of Last Patient Visit for Planned Analysis of prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus With or Without Lupus Nephritis and Provides Corporate Update Prula-cel topline results from planned analysis expected September 2026 FDA clearance of IND for ADI-212 in mCRPC; Phase 1 clinical study expected to initiate in 4Q 2026 Unveiling next-generation in vivo CAR-T platform and pipeli…
Read attachment ↗acet-ex99_1.htm · 8-K · 2026-08-05
EX-99.1 2 acet-ex99_1.htm EX-99.1 EX-99.1 Adicet Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates Company to provide a comprehensive Phase 1 clinical update for prulacabtagene leucel (prula-cel, formerly ADI-001), featuring data from 22 patients with lupus nephritis (LN) and systemic lupus erythematosus (SLE) with a minimum of 6 months follow-up, including 13 patients with at least 12 months of follow-up; topline results now anticipated in 3Q/2026 Productive…
Read attachment ↗